Pacific Biosciences vs DNAnexus

Side-by-side comparison of AI visibility scores, market position, and capabilities

DNAnexus leads in AI visibility (74 vs 53)
Pacific Biosciences logo

Pacific Biosciences

GrowthLife Sciences & BioTech

Long-Read Sequencing

Pioneer of single-molecule real-time (SMRT) long-read sequencing; Revio system targets clinical and research markets. Guides to $150–$170M FY2025 revenue with 40%+ gross margins.

AI VisibilityBeta
Overall Score
C53
Category Rank
#56 of 198
AI Consensus
79%
Trend
stable
Per Platform
ChatGPT
54
Perplexity
56
Gemini
48

About

Pacific Biosciences (PacBio) was founded in 2004 in Menlo Park, California and pioneered single-molecule real-time (SMRT) sequencing technology, enabling long-read DNA sequencing that can span tens of thousands of base pairs per read. This capability is essential for resolving complex genomic regions—structural variants, repeat expansions, methylation patterns, and full-length transcripts—that short-read platforms like Illumina cannot accurately assemble.\n\nPacBio's Revio system, launched in 2023, offers a dramatic improvement in throughput and cost efficiency over prior instruments, targeting both research and clinical sequencing laboratories. Key applications include rare disease diagnosis, pharmacogenomics, plant and animal genomics, and clinical oncology. The company guides to $150–$170 million in FY2025 revenue with gross margins exceeding 40% and a path to cash flow breakeven by 2027.\n\nPacBio competes primarily with Oxford Nanopore Technologies in the long-read segment, together driving adoption of long-read sequencing for comprehensive genome assembly and clinical applications. The company is expanding its high-accuracy (HiFi) chemistry and developing Onso, a short-read system, to capture a broader share of the sequencing market. With approximately $260 million in cash, PacBio is well-positioned to scale its clinical business.

Full profile
DNAnexus logo

DNAnexus

LeaderLife Sciences & BioTech

Precision Health Data Cloud Platform

DNAnexus is the leading precision health data cloud, managing 65+ petabytes of biomedical data for 12,000+ users across 48 countries; $200M Series I led by Blackstone Growth; serves 7 of top 10 pharma and 8 of top 10 diagnostics companies.

AI VisibilityBeta
Overall Score
B74
Category Rank
#4 of 198
AI Consensus
76%
Trend
stable
Per Platform
ChatGPT
78
Perplexity
75
Gemini
71

About

DNAnexus is the category-defining cloud platform for precision health data management, analysis, and collaboration. Founded in 2009 and headquartered in Mountain View, California, DNAnexus provides a secure, scalable, and regulatory-compliant cloud environment where pharmaceutical companies, genomics labs, biobanks, health systems, and research institutions can store, analyze, and share multimodal biomedical data — including genomic sequences, clinical records, imaging, and real-world evidence. The platform is purpose-built for the data types, compliance requirements, and computational workloads unique to biomedical research and precision medicine development.

Full profile

AI Visibility Head-to-Head

53
Overall Score
74
#56
Category Rank
#4
79
AI Consensus
76
stable
Trend
stable
54
ChatGPT
78
56
Perplexity
75
48
Gemini
71
51
Claude
71
49
Grok
68

Key Details

Category
Long-Read Sequencing
Precision Health Data Cloud Platform
Tier
Growth
Leader
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Pacific Biosciences
Long-Read Sequencing

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.